about
Drug interactions with new and investigational antiretrovirals.Predicting drug resistance of the HIV-1 protease using molecular interaction energy components.Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.Use of darunavir and enfuvirtide in a pregnant woman.
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Darunavir (TMC114): a new HIV-1 protease inhibitor.
@en
type
label
Darunavir (TMC114): a new HIV-1 protease inhibitor.
@en
prefLabel
Darunavir (TMC114): a new HIV-1 protease inhibitor.
@en
P2860
P1476
Darunavir (TMC114): a new HIV-1 protease inhibitor.
@en
P2093
Andrew Hill
Jean-Michel Molina
P2860
P304
P356
10.1517/14656566.8.12.1951
P407
P577
2007-08-01T00:00:00Z